Strategic Leadership Recent executive move with Dr. Myles Greenberg appointed as president and CEO suggests a potential pivot in corporate strategy and partnerships. This is an opportunity to align outreach with new leadership priorities, offering collaboration on clinical development, strategic financing, or partnership opportunities around their inhaled cardiovascular therapies.

Clinical Milestones Active advancement in RESTORE-1 pivotal Phase 3 study for InRhythm and FYI around paroxysmal atrial fibrillation indicates a near-term need for scalable support functions, CRO partnerships, data management, and clinical trial supply chain solutions to support ongoing trials and potential expansion into additional AF indications.

Remote Monitoring Alignment Existing collaboration with remote patient monitoring firm PhysIQ shows openness to digital health integration. This points to opportunities for BD discussions around wearables, real-time monitoring, data analytics, and remote patient engagement platforms to enhance safety, adherence, and post-market surveillance for inhaled therapies.

Regulatory and Market Readiness With soft funding and a clear focus on fast-acting, safe, at-home treatment across the continuum of care, there is demand for regulatory consulting, quality systems, and manufacturing scalability services to accelerate FDA interactions, keep pace with development timelines, and ensure compliant commercial readiness.

Funding and Partnerships Current funding of about $78M and revenue in early-stage range signal ongoing fundraising needs and potential for strategic alliances with larger biotechs or specialty pharma for co-development, licensing, or manufacturing collaborations to accelerate commercialization once clinical milestones are met.